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an open access article under the CC BY-NC-a b s t r a c t
We relate our experience with the Cook (Cook Medial Inc., Bloomington, IN, USA), triple-
lumen hyperalimentation (HAS) catheter for treatment related to autologous stem-cell
transplant. Nineteen HAS catheters were implanted in the right jugular vein, and tunneled
to the right anterior chest wall, under imaging guidance. Retrospectively, we reviewed each
catheter. Three patient's experienced “ballooning” of the middle (white) lumen of the HAS
catheter during routine use. We assessed, time in situ, follow-up imaging, chemotherapy
regimen, possibility of systemic or device infection, tissue pathology of the patient's ma-
lignancy, and other factors to attempt to determine if there were any associations that
could explain the catheter lumen failure. After this pilot study of the HAS-catheter in these
19 patients, we discontinued use of this device at our facility due to mechanical problems
of ballooned and obstructed middle lumens. There was no obvious cause, or association,
detected to explain the ballooning identified.
Copyright © 2016, the Authors. Published by Elsevier Inc. under copyright license from the
University of Washington. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction team to be trialed as a triple-lumen catheter. We report ourMultilumen venous access devices are extremely helpful
for the management of patients undergoing stem-cell trans-
plantation and have been shown to have manageable, if any,
side effects. [1] The multiple lumens allow for the dedicated
administration of medications, chemotherapy, fluids, blood
products, and alimentationwhen clinically required. Our local
stem-cell transplant teams had been using a dual-lumen
catheter and were in need of a triple-lumen catheter that
would enhance patient management and facilitate medical
and nursing care. The Cook hyperalimentation (HAS) catheter
was selected by the local Cancer Agency Stem-Cell Transplantlared that no competing i
(B. Burbridge).
blished by Elsevier Inc. u
ND license (http://creativexperience with this device in 19 patients.
Thiswasa retrospective reviewof thepatient’s imagingand
medical history for the purposes of a Quality Assurance proj-
ect. As such, our local Research Ethics Committee waived the
requirement for a full ethical reviewandapproved this project.Materials and methods
The HAS catheter is described in manufacturer’s product
literature to, “provide for the intravenous administration of
nutrient fluids, chemotherapeutic agents, therapeutic drugs,nterests exist.
nder copyright license from the University of Washington. This is
ecommons.org/licenses/by-nc-nd/4.0/).
Fig. 2 e Fluoroscopy imaging after catheter insertion.
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monitoring” (Cook Medical Inc., Bloomington, IN, USA). The
device used was a triple-lumen, 12.5F with the large lumen of
the catheter able to accommodate a 0.038-in guidewire. The
lumen configuration of the HAS catheter reveals 2 large, half-
lunar shaped lumens with a very small third lumen inter-
posed between the 2 large lumens (see Fig. 1).
Sequential patients enrolled in the autologous stem-cell
transplant program received the HAS catheter.
All of the HAS catheters assessed in this study were
implanted by interventional radiology using ultrasound and
fluoroscopic guidance for proper catheter positioning with the
final catheter tip at the superior vena cavaeright atrial junc-
tion (see Fig. 2).
Right internal jugular venous access was achieved, with
ultrasound and fluoroscopic guidance (see Fig. 3). The HAS
catheter was tunneled from an anterior chest wall location to
the internal jugular vein access site. The catheterwas supplied
with a standard 25-cm length, which was cut to a length that
suited the patient’s anatomy. Using a 13F peel-away sheath
(Cook Medial Inc., Bloomington, IN, USA), the catheter was
manipulated to the superior vena cavaeright atrial junction
using fluoroscopy. The catheters were fixated to the patient by
applying 2, nonabsorbable, Prolene skin sutures using the
built-in catheter suturing wings (Ethicon US LLC, Somerville,
NJ, USA). The 3 lumens of the catheter were flushed and closed
with a solution of sterile, heparinized saline (100 IU heparin
sulfate/mL, Pharmaceutical Partners of Canada, Richmond
Hill, ON, Canada). All implanted catheters were functioning
satisfactorily at the completion of implantation.Results
All catheter implantations were successful at the primary
visit, resulting in a 100% technical success rate. The right in-
ternal jugular vein and the right anterior chest were used for
all patients. No implantation complications were encoun-
tered. There was no unusual angulation of any of the cathe-
ters at the jugular vein insertion site or in the chest wall.Fig. 1 e An image of the distal end of the HAS catheter
demonstrates the configuration of the 3 lumens with the
small, middle lumen interposed between the 2 large half-
moon shaped lumens.Nineteen patients received the HAS catheter for treatment.
There were 9 females and 10males. Their age ranged between
30 and 71 years (mean ¼ 53).
Ten of the patients were being treated for Multiple
Myeloma, whereas the other 9 had some form of lymphoma.
Three patients experienced “ballooning” (see Fig. 4) of the
middle (white) lumen of their HAS catheter. The “ballooning”
was not a permanent deformity, and was most pronounced
during attempts to use the middle (white) lumen. Once the
“ballooned” catheters were removed amild contour bulge was
obvious on general inspection. The initial detection of these
ballooning events occurred at 15, 19, and 20 days post-HAS-
catheter insertion. The ballooned lumens were all occluded,
and the deformity of the catheter occurred with forceful
flushing by the clinical team. These catheters were not
removed after ballooning because the remaining 2 lumens
(blue and red) were still functional.
We performed a retrospective review of all 19 patient’s
charts to look for any possible explanation for this complica-
tion. Ballooning of the white lumen occurred during routine
flushing by 3 different nurses assigned to each patient’s care
in all 3 cases. A different interventional radiologist implanted
each of these ballooned catheters.
All 3-ballooned catheters were implanted in male patients.
Seven of the 19 patients had a positive blood culture during
the course of their catheter insertion, while receiving stem-
cell transplant inpatient treatment. Two of these 7 patients
also experienced ballooning of the white lumen.
Patients had anywhere from 0 to 9 chest x-rays, while the
catheter was implanted, with patients having an average of 3
(standard deviation ¼ 2.0). One of the chest x-rays revealed
Fig. 3 e Chest x-ray 1-day postcatheter insertion. (A) posterior-anterior view; (B) lateral view.
Fig. 4 e Images of the 3 catheters with “ballooned” middle (white) lumens of the Cook triple-lumen HAS catheter. (A) This
image set demonstrates the catheter before injection (left image) and during the injection of saline (right image). (B) Images
of catheters from 2 additional patients demonstrating the middle lumen ballooning during the injection of saline.
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Table 1 e Summary of subject device data, demographics, diagnoses, and complications.
Feature All catheters (n ¼ 19) Ballooned catheters (n ¼ 3) Unaffected catheters (n ¼ 16)
Gender male 10 3 7
Gender female 9 0 9
Subject age range (years) 30-71 35-58 30-71
Subject age mean (years) 53 48 55
Days in situ range (days) 28-93 44-55 28-93
Days in situ mean (days) 48 51 47
Multiple myeloma 10 0 10
Lymphoma 9 3 6
Positive blood culture 7 2 5
No positive blood cultures 13 1 12
Catheter migration 1 0 1
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catheter did not ascend outside the superior vena cava. This
partially retracted catheter did not demonstrate ballooning of
the middle lumen. There were no other clinically or radio-
graphically demonstrated catheter-migration issues.
Patients were undergoing 1 of 3 different chemotherapy
protocols, while they had their catheters in place. All 3 epi-
sodes of had catheter ballooning occurred in patients who
were being treated for lymphoma.
All results are summarized in Table 1.Discussion
Our experience with the Cook, triple-lumen HAS catheter
resulted in a 100% catheter implantation success rate. The
catheter was used per the manufacturers instructions for use,
and there were no off label catheter use. In general, it is ex-
pected that complication rates with central venous catheter
use is around 15%; however, this includes infection and
thrombotic problems, whichwe did not encounter. [2] The 3 of
19 occurrences of catheter ballooning results in a 15.8% rate
for this complication. A detailed review of current literature
makes no mention of catheters ballooning as a result of a
lumen obstruction.
We failed to find a definitive explanation, or statistically
significant association, for this unique and unusual HAS-
catheter complication. We investigated a potential infectious
cause, finding that 7 of the 19 patients had a positive blood
cultures during the period of catheter utilization. However,
only 2 of the 3 patients with the ballooning complication had a
positive culture and 5 other patients had a positive culture,
without ballooning. The 3 patients that experienced
ballooning of the middle lumen were all on the same
chemotherapy protocol, as were 4 other patients who did not
experience ballooning.We examined the clinical scenario for each episode of
ballooning by thoroughly reviewing the patient’s inpatient
medical record. The common trend, found in the nurse’s
notes in the patient’s chart, indicated that the middle lumen
would not flush when routine saline flushing was attempted,
the lumen would then balloon when additional force was
applied, leading to imaging confirming the ballooned lumen
during a fluoroscopic assessment of the catheter. None of the
ballooned catheters had additional obstructed lumina, nor did
they demonstrate evidence of catheter tip fibrin sheath for-
mation. Ballooning occurred at 15, 19, and 20 day’s after im-
plantation, which equates to about the midway point of their
time in situ.
This leaves us at a loss to explain this unusual complica-
tion that we experienced. This product is manufactured
individually, and it is important to note that our request to try
the Cook, HAS catheter, required an increase in production.
Therefore, this complication may be attributable to a
manufacturing problem but more investigation into this the-
ory is required.
The HAS catheter was of benefit to the patients who
received it as a part of their stem-cell transplant care, as the
third lumen was considered to be of high clinical value.
However, these benefits were insufficient in the face of this
unique complicationwe experienced andwe discontinued use
of this venous access device.r e f e r e n c e s
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